Want to see IN:GLENMARK full AI Analyst Report?

Glenmark Pharmaceuticals Limited (GLENMARK) Price & Analysis

5 Followers

GLENMARK Stock Chart & Stats

₹2065.95

-₹29.45(-1.81%)

At close: Jan 09 4:00 PM EST

₹2065.95

-₹29.45(-1.81%)

Day’s Range― - ―

52-Week Range₹1,794.00 - ₹2,536.85

Previous CloseN/A

Volume301.32K

Average Volume (3M)28.97K

Market Cap

₹710.47B

Enterprise Value₹596.10K

Total Cash (Recent Filing)₹11.76B

Total Debt (Recent Filing)₹5.94B

Price to Earnings (P/E)38.9

Beta0.54

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.2%

Share Statistics

EPS (TTM)48.26

Shares Outstanding282,224,670

10 Day Avg. Volume44,119

30 Day Avg. Volume28,971

Financial Highlights & Ratios

PEG Ratio1.47

Price to Book (P/B)5.72

Price to Sales (P/S)3.54

P/FCF Ratio30.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)82.23

Revenue Forecast (FY)₹167.88B

Bulls Say, Bears Say

Bulls Say

Steady Revenue GrowthSustained revenue expansion indicates Glenmark is growing its commercial scale across branded, generic and API businesses. Continued top-line progress can support operating leverage and provide a broader base for future product launches and therapeutic-area growth.

Profitability ReboundThe return to healthy operating and net margins demonstrates that Glenmark can convert improved revenue scale and business execution into profits. If maintained, stronger profitability should improve internal funding capacity and resilience across product cycles.

Much Lower LeverageThe sharply reduced leverage materially lowers financial risk and interest-related pressure. A conservatively positioned balance sheet gives Glenmark greater flexibility to fund manufacturing, product development and market expansion while absorbing operational volatility.

Bears Say

Earnings VolatilityLarge earnings swings indicate that recent profitability has not yet proven consistent through business or product-cycle changes. This reduces earnings predictability and makes it harder to assess the durability of margins and sustainable returns.

Inconsistent Cash GenerationThe history of negative operating and free cash flow shows that reported earnings have not always translated reliably into cash. Continued inconsistency could constrain reinvestment, debt flexibility and the company’s ability to self-fund growth.

Recent Free Cash Flow DeclineAlthough FY2026 free cash flow was positive, its year-on-year decline highlights pressure on cash conversion after the recovery. If this persists, Glenmark may have less internally generated funding for product launches, capacity investment and shareholder returns.

Glenmark Pharmaceuticals Limited News

Glenmark Enters $70 Million U.S. Calcium Gluconate Market With New Injectables Launch

Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) has shared an update. Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate...

12d ago

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for...

13d ago

Glenmark Launches Generic Olanzapine Injection in U.S. Institutional Market

Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) has shared an update. Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for...

2M ago

Glenmark Advances Global Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer

An update from Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) is now available. Glenmark Specialty S.A., a wholly owned...

2M ago

Glenmark to Shift Nebulizer IP to Subsidiary in Strategic Respiratory Push

The latest announcement is out from Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ). Glenmark Pharmaceuticals has approved the transfer...

3M ago

Glenmark’s U.S. Unit Reaches $29.6 Million Antitrust Settlement With State Attorneys General

Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) has provided an update. Glenmark Pharmaceuticals’ U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA,...

3M ago

Glenmark Launches Low-Cost Semaglutide GLIPIQ in India to Expand Diabetes Care

The latest announcement is out from Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ). Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide)...

6M ago

Glenmark launches low-cost semaglutide GLIPIQ in India to widen diabetes care access

Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) has provided an update. Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India...

6M ago

Glenmark Wins U.S. FDA Nod and 180-Day Exclusivity for Generic FloVent Inhaler

An update from Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) is now available. Glenmark Specialty SA, a unit of...

6M ago

Glenmark to Enter $66.8 Million U.S. Sodium Phosphates Injection Market in April

An update from Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) is now available. Glenmark Pharmaceuticals Inc., USA, a subsidiary...

6M ago

GLENMARK FAQ

What was Glenmark Pharmaceuticals Limited’s price range in the past 12 months?

Glenmark Pharmaceuticals Limited lowest stock price was ₹1794.00 and its highest was ₹2536.85 in the past 12 months.

What is Glenmark Pharmaceuticals Limited’s market cap?

Glenmark Pharmaceuticals Limited’s market cap is ₹710.47B.

When is Glenmark Pharmaceuticals Limited’s upcoming earnings report date?

Glenmark Pharmaceuticals Limited’s upcoming earnings report date is Nov 06, 2026 which is in 66 days.

How were Glenmark Pharmaceuticals Limited’s earnings last quarter?

Glenmark Pharmaceuticals Limited released its earnings results on Jul 31, 2026. The company reported ₹17.11 earnings per share for the quarter, missing the consensus estimate of ₹17.3 by -₹0.19.

Is Glenmark Pharmaceuticals Limited overvalued?

According to Wall Street analysts Glenmark Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Glenmark Pharmaceuticals Limited pay dividends?

Glenmark Pharmaceuticals Limited pays a Monthly dividend of ₹2.5 which represents an annual dividend yield of 0.2%. See more information on Glenmark Pharmaceuticals Limited dividends here

What is Glenmark Pharmaceuticals Limited’s EPS estimate?

Glenmark Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Glenmark Pharmaceuticals Limited have?

Glenmark Pharmaceuticals Limited has 282,224,670 shares outstanding.

What happened to Glenmark Pharmaceuticals Limited’s price movement after its last earnings report?

Glenmark Pharmaceuticals Limited reported an EPS of ₹17.11 in its last earnings report, missing expectations of ₹17.3. Following the earnings report the stock price went up 1.928%.

Which hedge fund is a major shareholder of Glenmark Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:GLENMARK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.